Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05 for the treatment major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial for the treatment of Alzheimer’s disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS-07 for the treatment of migraine; AXS-12 for the treatment of narcolepsy; and AXS-14 for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Search:
You do not have permission to access this chart.
Please Sign Up or Login
News for Axsome Therapeutics, Inc. (AXSM)
minutes ago | Banggood.com
58 minutes ago | Aliexpress.com
a day ago | The Motley Fool
2 days ago | Newsfile Corp
3 days ago | Newsfile Corp
3 days ago | The Motley Fool
4 days ago | Business Wire
4 days ago | Newsfile Corp
4 days ago | Business Wire
4 days ago | Business Wire
5 days ago | The Motley Fool
5 days ago | Zacks Investment Research